Product Highlights

• A gold standard in nonionic contrast agents¹
• A universal, nonionic, low osmolar contrast medium²
• The leading iodinated diagnostic imaging agent around the world¹
• Experience across all indications and patient groups²
• More than 4,000 published clinical studies and over 35 published doctoral theses¹
• Over 200,000,000 examinations to date¹
• Providing high-quality contrast for over 20 years¹

Product Description

A low osmolar, nonionic, iodinated contrast agent introduced in the U.S. in 1985, OMNIPAQUE has been used in more than 100 million patients worldwide. Its indications include a broad range of intravascular diagnostic procedures such as coronary angiography, spinal cord imaging, and body cavity procedures including shoulder and knee joints. OMNIPAQUE is approved for use in adults and children, and is available in a wide variety of packagings that meet the needs of safety, convenience, and cost efficiency.

References: 1. Data on file, Amersham Health. 2. OMNIPAQUE Prescribing Information.

OMNIPAQUE 140 and 350 mgl/mL ARE NOT FOR INTRATHECAL USE. All nonionic, iodinated contrast media currently available inhibit blood coagulation, in vitro, less than ionic contrast media. Clotting has been reported when blood remains in contact with syringes containing nonionic contrast media. Serious, rarely fatal, thromboembolic events causing myocardial infarction and stroke have been reported during angiographic procedures with both ionic and nonionic contrast media. Therefore, meticulous intravascular administration technique is necessary to minimize thromboembolic events.